Gene Therapy Strategies for Duchenne Muscular Dystrophy Utilizing Recombinant Adeno-associated Virus Vectors

This publication has 53 references indexed in Scilit:

• Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective
  Molecular Therapy, 2004
• Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1
  Blood, 2004
• From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel Vectors for Human Gene Therapy
  Current Gene Therapy, 2003
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
  Blood, 2003
• Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product
  Gene Therapy, 2002
• Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
  Nature Medicine, 2002
• The dystrophin–glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies
  Muscle & Nerve, 2001
• Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
  Nature Medicine, 2001
• Route of Administration Determines Induction of T-Cell-Independent Humoral Responses to Adeno-Associated Virus Vectors
  Molecular Therapy, 2000
• The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
  Cell, 1988